XORTX Therapeutics: Meeting Documents Now Available
![XORTX Therapeutics: Meeting Documents Now Available](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
XORTX Announces Filing and Mailing of Meeting Documents
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, has made significant announcements regarding its upcoming annual and special meeting of shareholders. The management information circular for the meeting is now accessible on the Company’s corporate website as part of their commitment to transparency and shareholder engagement.
Availability of Meeting Documents
The management information circular contains crucial details about the upcoming meeting. Shareholders are encouraged to review the materials thoroughly. This circular is available not only on XORTX's official site but also on SEDAR+ and SEC’s websites. Access to these documents ensures that all shareholders have the information needed to make informed decisions regarding their votes.
Important Meeting Details
XORTX has scheduled the annual and special meeting on September 12 at 10:00 AM (Calgary Time). This meeting will take place at the Company’s offices located at 3710 – 33rd Street NW. It is imperative for shareholders to participate and cast their votes, reinforcing the importance of every vote, irrespective of the number of shares owned.
Voting Process and Guidelines
Shareholders should act swiftly; the deadline for voting is set for 10:00 AM on September 10. With XORTX’s strategic advisor and proxy solicitation agent, Laurel Hill Advisory Group, available for assistance, shareholders can reach out for help with any voting inquiries by calling 1-877-452-7184 or emailing at assistance@laurelhill.com.
Clarification of Important Information
The circular also contains a clarification regarding the participation of directors in prior board meetings. Specifically, it corrects the misreported attendance record of Patrick Treanor, who was not a member of the board during those meetings in 2023. This correction aims to provide shareholders with an accurate representation of board activities.
Overview of XORTX Therapeutics Inc.
XORTX is at the forefront of developing pharmaceutical solutions, with two notable products in late-stage clinical development. The lead program, XRx-008, targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), while the secondary program, XRx-101, addresses acute kidney and organ injuries associated with infections such as COVID-19. Additionally, XORTX is advancing XRx-225, which is in the pre-clinical stage focused on Type 2 Diabetic Nephropathy.
Clinical Development Focus
The Company’s focus on innovative therapies stems from its understanding of aberrant purine metabolism and the importance of xanthine oxidase inhibition in the treatment of various kidney diseases. With a commitment to improving patient quality of life, XORTX continues to work diligently on its clinical stages of development.
Contact Information for Shareholders
For any inquiries, shareholders can contact Allen Davidoff, CEO, at adavidoff@xortx.com or +1 403 455 7727. Additionally, Nick Rigopulos, Director of Communications, is available for questions at nick@alpineequityadv.com or +1 617 901 0785. Kim Golodetz from LHA Investor Relations can also assist at kgolodetz@lhai.com or +1 212 838 3777.
Frequently Asked Questions
What is the purpose of the XORTX annual meeting?
The annual meeting is designed for shareholders to receive updates from the company, discuss financial performance, and vote on key business matters.
When is the deadline for shareholders to vote?
The deadline for voting is 10:00 AM (Calgary Time) on September 10.
How can shareholders access the management circular?
Shareholders can access the management circular on XORTX's website and through SEDAR+ and SEC websites.
Who should shareholders contact for voting assistance?
Shareholders should reach out to Laurel Hill Advisory Group for assistance with voting.
What are the main products in development by XORTX?
XORTX is developing XRx-008 and XRx-101, targeting kidney diseases and related conditions, with another program in the pre-clinical stage for diabetic nephropathy.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- INVL Baltic Real Estate Shareholders Meeting Resolutions
- DIAGNOS Schedules 2024 Annual General Meeting Announcement
- LITGRID AB Extraordinary General Meeting Notice
- Allsup Proudly Sponsors the Walk to End Lupus Now
- Brian Marynowitz Receives 2024 Emerging Leader Award
- Register Now for the 2024 California Economic Summit
- Clover Leaf Capital Corp. Updates Special Meeting Schedule
- Kuke Music Holding Limited Annual Meetings Announcement
- FDA Meeting for Zynquista Approval by Lexicon Pharmaceuticals
- Chuy’s Holdings Confirms Special Meeting Dates for Stockholders